- Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, one of the very few peptides in this database with an approved indication studied specifically in women.
- Its efficacy evidence base is female-direct rather than male-extrapolated, because the registration trials were run primarily in women for that indication.
- Even so, its as-needed use was not evaluated against specific menstrual cycle phases, and efficacy in postmenopausal women was not established, so a female-approved compound still carries open questions.
Almost every compound in this database gets measured against a male-built evidence base. PT-141 is the exception that makes the standard visible. Bremelanotide, marketed as Vyleesi, is a melanocortin receptor agonist that reached FDA approval for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its supporting studies were run primarily in women, which makes its evidence genuinely female-direct. This profile treats it as a worked example: how to read a real female indication honestly, without letting "approved in women" slide into "answered for all women."
The mechanism that set it apart
Bremelanotide acts as a non-selective agonist at melanocortin receptors, primarily MC4R, in the central nervous system, where it modulates dopaminergic pathways involved in sexual desire. That central, receptor-level mechanism is what distinguished it from earlier peripheral approaches to sexual-function research and is why it has been studied as a distinct research material rather than a variation on existing ones.
What "female-direct" actually earns
Because the trials were designed and run in the target female population, the sex-difference field here is marked as evidence, not extrapolation. That is a meaningful distinction. For most peptides, a claim about women rests on inference from male or mixed studies. For PT-141, the claim about premenopausal women with HSDD rests on studies of premenopausal women with HSDD. This is what the top of the evidence hierarchy looks like in this space.
What the label still leaves open
An approval is a boundary, not a blanket. Several female-relevant questions remain unanswered even here. As-needed dosing was not evaluated against specific menstrual cycle phases in the registration trials, so cycle timing is not characterized. The approved indication is premenopausal women, and efficacy in postmenopausal women was not established, so the evidence does not extend past that line. On drug interactions, no clinically significant interaction with oral contraceptives was identified in the approval data, which is a real finding, though a narrower one than "no interactions exist."
| Female-angle question | Evidence state in the source material |
|---|---|
| HSDD efficacy in premenopausal women | Direct female evidence; the approved indication |
| Sex differences | Evidence; trialed primarily in women |
| Menstrual cycle phase | Unstudied; as-needed use not evaluated by phase |
| Postmenopausal women | No evidence; efficacy not established |
| Oral contraceptive interaction | No clinically significant interaction identified |
| Pregnancy and lactation | Not recommended in pregnancy; lactation effects not established |
The source material lists an approved subcutaneous, as-needed dose for reference. That figure belongs to the label and is not a protocol, instruction, or medical advice from this site. We do not publish personal dosing. Any decision to use an approved medicine belongs with a licensed clinician.
Bremelanotide is not recommended in pregnancy, and the label directs discontinuation if pregnancy is suspected. Its effects during lactation are not established. Approval for one female population does not make it safe across all of them.
Why the counter-example matters
PT-141 is valuable to this database not because it is dramatic but because it is honest to model. It shows that female-direct evidence is possible, that it changes what you are allowed to say, and that even then the record has edges: cycle phase, menopausal status, and pregnancy remain open or bounded. The full field-by-field breakdown is on the bremelanotide (PT-141) profile.